Overview

This trial is active, not recruiting.

Condition atrial fibrillation
Sponsor University of Dundee
Collaborator NHS Tayside
Start date March 2010
End date March 2011
Trial size 5000 participants
Trial identifier NCT01081327, ELD007

Summary

Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model ecologic or community
Time perspective retrospective
Arm

Primary Outcomes

Measure
Bleeding Complication
time frame: 10 years
Cardiovascular outcome
time frame: 10 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Prescription for Warfarin - Atrial Fibrillation Exclusion Criteria: - Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma. - Conditions with increased risk of bleeding.

Additional Information

Official title Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by University of Dundee.